NEW YORK (GenomeWeb) – German molecular diagnostics firm New Oncology today announced a collaboration with the University Hospital Oslo aimed at guiding treatment of patients with targeted cancer therapies.

Financial details of the agreement weren't disclosed, but New Oncology, the molecular diagnostics division of genomic analytics firm Blackfield, said that under the collaboration it will use its next-gen sequencing diagnostic platform, Neo, to identify alterations in cancer-related genes that predict a patient's response or resistance to targeted therapies.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.